Lantern Pharma Inc.
NASDAQ:LTRN
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.94
10.65
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LTRN stock under the Base Case scenario is 3.83 USD. Compared to the current market price of 3.08 USD, Lantern Pharma Inc. is Undervalued by 20%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Lantern Pharma Inc.
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LTRN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Lantern Pharma Inc.
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Lantern Pharma Inc.
Balance Sheet Decomposition
Lantern Pharma Inc.
Current Assets | 29.9m |
Cash & Short-Term Investments | 28.1m |
Other Current Assets | 1.9m |
Non-Current Assets | 372.3k |
PP&E | 335.6k |
Other Non-Current Assets | 36.7k |
Current Liabilities | 3.6m |
Accounts Payable | 3.4m |
Accrued Liabilities | 197.3k |
Non-Current Liabilities | 94k |
Other Non-Current Liabilities | 94k |
Earnings Waterfall
Lantern Pharma Inc.
Revenue
|
0
USD
|
Operating Expenses
|
-21.2m
USD
|
Operating Income
|
-21.2m
USD
|
Other Expenses
|
2.1m
USD
|
Net Income
|
-19.1m
USD
|
Free Cash Flow Analysis
Lantern Pharma Inc.
USD | |
Free Cash Flow | USD |
LTRN Profitability Score
Profitability Due Diligence
Lantern Pharma Inc.'s profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Lantern Pharma Inc.'s profitability score is 47/100. The higher the profitability score, the more profitable the company is.
LTRN Solvency Score
Solvency Due Diligence
Lantern Pharma Inc.'s solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Lantern Pharma Inc.'s solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LTRN Price Targets Summary
Lantern Pharma Inc.
According to Wall Street analysts, the average 1-year price target for LTRN is 22.44 USD with a low forecast of 18.18 USD and a high forecast of 27.3 USD.
Dividends
Current shareholder yield for LTRN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
LTRN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2020-06-11. The firm is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.
Contact
IPO
Employees
Officers
The intrinsic value of one LTRN stock under the Base Case scenario is 3.83 USD.
Compared to the current market price of 3.08 USD, Lantern Pharma Inc. is Undervalued by 20%.